HR and neoplasm: In terms of tumor subtype according to hormone receptor (HR) and HER2 status, HR(+)/HER2(−) was found to be the most common (52.9%); moreover, 58.8, 71.3, and 69.8% of patients received radiation therapy, chemotherapy, and antihormonal therapy, respectively (Table 1).